Skip to main content

Leukemia

Prognostic Significance of Concomitant Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML

Decitabine + Venetoclax versus Intensive Chemotherapy for Patients with Relapsed/Refractory AML: A Propensity Score–Matched Analysis

Escalated Dosing Schedules of CC-486 Effective for Patients Experiencing First AML Low Blast Count Relapse

Gilteritinib + Azacitidine or Azacitidine Alone in Patients with Newly Diagnosed, FLT3-Mutated Acute Myeloid Leukemia

Comparative Effectiveness of Glasdegib or Venetoclax in Combination with Low-Dose Cytarabine Using Simulated Treatment Comparisons

Phase 1b/2 Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies

Safety and Efficacy of Decitabine + Ipilimumab in Relapsed/Refractory MDS/AML in Posttransplant or Transplant-Naïve Settings

The First-in-Class Anti-CD47 Antibody Magrolimab + Azacitidine Is Well-Tolerated and Effective in Patients with AML

Venetoclax Added to Cladribine plus Low-Dose Ara-C Alternating with 5-Azacitidine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

MBG453 in Combination with Hypomethylating Agents in Patients with High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

2
3
4
5
6
7
8

Page 5 of 8
Results 41 - 50 of 78